Details of the Drug

General Information of Drug (ID: DM2NUH3)

Drug Name
Imipramine
Synonyms
Antideprin; Berkomine; Censtim; Censtin; Declomipramine; Dimipressin; Dpid; Dynaprin; Eupramin; Imavate; Imidobenzyle; Imipramin; Imipramina; Imipraminum; Imiprin; Imizin; Imizinum; Impramine; Intalpram; Iramil; Irmin; Janimine; Melipramin; Melipramine; Nelipramin; Norchlorimipramine; Norfranil; Pramine; Prazepine; Promiben;Psychoforin; Surplix; Timolet; Tofranil; Imipramina [Italian]; Tofraniln A; Antideprin (TN); Deprimin (TN); Deprinol (TN); Depsonil (TN); Dyna-zina; Dynaprin (TN); Eupramin (TN); G-22355; Imipramil (TN); Imipramina [INN-Spanish]; Imipramine (INN); Imipramine [INN:BAN]; Imipraminum [INN-Latin]; Irmin (TN); Janimine (TN); Janimine (hydrochloride); Melipramin (TN); SK-Pramine; Surplix (TN); Tofranil(TN); Tofranil (free base); Tofranil (hydrochloride); Tofranil, base; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(gamma.-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-(9CI)
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1], [2], [3]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 280.4
Topological Polar Surface Area (xlogp) 4.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-1.5 h [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Bioavailability
The bioavailability of drug is 62% [4]
Clearance
The clearance of drug is 1 L/h/kg [6]
Elimination
Imipramine is primarily excreted in the urine with less than 5% present as the parent compound [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 12 hours [6]
Metabolism
The drug is metabolized via the liver [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.0944 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.075% [8]
Vd
The volume of distribution (Vd) of drug is 10-20 L/kg [6]
Chemical Identifiers
Formula
C19H24N2
IUPAC Name
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
Canonical SMILES
CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
InChI
InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
InChIKey
BCGWQEUPMDMJNV-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3696
ChEBI ID
CHEBI:47499
CAS Number
50-49-7
DrugBank ID
DB00458
TTD ID
D06ZUK
VARIDT ID
DR00552
INTEDE ID
DR0861
ACDINA ID
D00325

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [9], [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [14]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [15]
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [16]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [16]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [17]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [16]
Docosahexaenoic acid omega-hydroxylase (CYP4F11) DEIZLTN CP4FB_HUMAN Substrate [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Norepinephrine transporter (NET) DTT SLC6A2 7.05E-01 7.02E-03 0.07
P-glycoprotein 1 (ABCB1) DTP P-GP 7.83E-01 4.69E-02 1.89E-01
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 7.90E-01 3.72E-02 2.95E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.87E-01 4.98E-02 3.61E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 5.79E-01 -1.30E-02 -9.78E-02
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.68E-01 3.64E-02 2.72E-01
Docosahexaenoic acid omega-hydroxylase (CYP4F11) DME CYP4F11 6.86E-01 -4.38E-02 -2.46E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.66E-01 9.19E-03 4.88E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Imipramine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Imipramine and Cyclobenzaprine. Depression [6A70-6A7Z] [98]
Fluoxetine DM3PD2C Major Decreased metabolism of Imipramine caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [99]
Nortriptyline DM4KDYJ Moderate Additive anticholinergic effects by the combination of Imipramine and Nortriptyline. Depression [6A70-6A7Z] [100]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Imipramine and Vilazodone. Depression [6A70-6A7Z] [98]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Imipramine and Nefazodone. Depression [6A70-6A7Z] [98]
Paroxetine DM5PVQE Major Decreased metabolism of Imipramine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [101]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Imipramine and Selegiline. Depression [6A70-6A7Z] [102]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Imipramine and Vortioxetine. Depression [6A70-6A7Z] [98]
Duloxetine DM9BI7M Major Additive serotonergic effects by the combination of Imipramine and Duloxetine. Depression [6A70-6A7Z] [98]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Imipramine and Isocarboxazid. Depression [6A70-6A7Z] [102]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Imipramine and Milnacipran. Depression [6A70-6A7Z] [98]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Imipramine and Escitalopram. Depression [6A70-6A7Z] [103]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Imipramine and Tranylcypromine. Depression [6A70-6A7Z] [102]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Imipramine and Desvenlafaxine. Depression [6A70-6A7Z] [98]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Imipramine and OPC-34712. Depression [6A70-6A7Z] [100]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Imipramine and Phenelzine. Depression [6A70-6A7Z] [102]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Imipramine and Clomipramine. Depression [6A70-6A7Z] [100]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Imipramine and Trazodone. Depression [6A70-6A7Z] [98]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Imipramine and Amoxapine. Depression [6A70-6A7Z] [100]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Imipramine and Doxepin. Depression [6A70-6A7Z] [100]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Imipramine and Maprotiline. Depression [6A70-6A7Z] [100]
⏷ Show the Full List of 21 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Imipramine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Imipramine and Methylene blue. Acquired methaemoglobinaemia [3A93] [102]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Imipramine and Ivosidenib. Acute myeloid leukaemia [2A60] [104]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Imipramine and Midostaurin. Acute myeloid leukaemia [2A60] [105]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Imipramine and Idarubicin. Acute myeloid leukaemia [2A60] [105]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Imipramine and Daunorubicin. Acute myeloid leukaemia [2A60] [105]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Imipramine and Arn-509. Acute myeloid leukaemia [2A60] [106]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Imipramine and Gilteritinib. Acute myeloid leukaemia [2A60] [107]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Imipramine and Oliceridine. Acute pain [MG31] [108]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Imipramine and Scopolamine. Addictive disorder [6C50-6C5Z] [100]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Imipramine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [109]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Imipramine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [109]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Imipramine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [100]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Imipramine and Memantine. Alzheimer disease [8A20] [100]
Galantamine DMEO794 Moderate Antagonize the effect of Imipramine when combined with Galantamine. Alzheimer disease [8A20] [110]
Rivastigmine DMG629M Moderate Antagonize the effect of Imipramine when combined with Rivastigmine. Alzheimer disease [8A20] [110]
Donepezil DMIYG7Z Moderate Antagonize the effect of Imipramine when combined with Donepezil. Alzheimer disease [8A20] [110]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Imipramine and Metronidazole. Amoebiasis [1A36] [111]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Imipramine and Ivabradine. Angina pectoris [BA40] [106]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Imipramine and Bepridil. Angina pectoris [BA40] [112]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Imipramine and Dronedarone. Angina pectoris [BA40] [105]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Imipramine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [113]
Buspirone DMBS632 Major Additive serotonergic effects by the combination of Imipramine and Buspirone. Anxiety disorder [6B00-6B0Z] [98]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Imipramine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [100]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Imipramine and Cilostazol. Arterial occlusive disease [BD40] [105]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Imipramine and Voriconazole. Aspergillosis [1F20] [105]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Imipramine and Desipramine. Attention deficit hyperactivity disorder [6A05] [100]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Imipramine caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [114]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Imipramine and Ofloxacin. Bacterial infection [1A00-1C4Z] [115]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Imipramine and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [105]
Dalfopristin DM4LTKV Major Decreased metabolism of Imipramine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [116]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Imipramine and Clarithromycin. Bacterial infection [1A00-1C4Z] [105]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Imipramine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [105]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Imipramine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [115]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Imipramine and Linezolid. Bacterial infection [1A00-1C4Z] [117]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Imipramine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [115]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Imipramine and Norfloxacin. Bacterial infection [1A00-1C4Z] [115]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Imipramine and Levofloxacin. Bacterial infection [1A00-1C4Z] [115]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Imipramine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [105]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Imipramine and Telithromycin. Bacterial infection [1A00-1C4Z] [105]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Imipramine and Retigabine. Behcet disease [4A62] [105]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Imipramine and Cariprazine. Bipolar disorder [6A60] [100]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Imipramine and Loperamide. Bowel habit change [ME05] [118]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Imipramine and Lapatinib. Breast cancer [2C60-2C6Y] [105]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Imipramine and Tamoxifen. Breast cancer [2C60-2C6Y] [105]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Imipramine and Toremifene. Breast cancer [2C60-2C6Y] [105]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Imipramine and Sotalol. Cardiac arrhythmia [BC9Z] [105]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Imipramine when combined with Acetylcholine. Cataract [9B10] [119]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Imipramine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [120]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Imipramine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [121]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Imipramine and Dihydrocodeine. Chronic pain [MG30] [108]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Imipramine and Levomilnacipran. Chronic pain [MG30] [98]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Imipramine and Oxaliplatin. Colorectal cancer [2B91] [105]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Imipramine and Olopatadine. Conjunctiva disorder [9A60] [122]
Mestranol DMG3F94 Minor Decreased metabolism of Imipramine caused by Mestranol. Contraceptive management [QA21] [123]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Imipramine and Halothane. Corneal disease [9A76-9A78] [105]
Alfentanil DMVO0UB Moderate Additive CNS depression effects by the combination of Imipramine and Alfentanil. Corneal disease [9A76-9A78] [108]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Imipramine and Remifentanil. Corneal disease [9A76-9A78] [108]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Imipramine and Probucol. Coronary atherosclerosis [BA80] [105]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Imipramine and Clofazimine. Crohn disease [DD70] [124]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Imipramine and Mifepristone. Cushing syndrome [5A70] [105]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Imipramine and Pasireotide. Cushing syndrome [5A70] [105]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Imipramine and Osilodrostat. Cushing syndrome [5A70] [106]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Imipramine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [125]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Imipramine and Ethanol. Cystitis [GC00] [126]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Imipramine and Mepenzolate. Digestive system disease [DE2Z] [100]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Imipramine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [127]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Imipramine and Oxybutynine. Discovery agent [N.A.] [100]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Imipramine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [105]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Imipramine and Meclizine. Dizziness and giddiness [MB48] [100]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Imipramine and Deutetrabenazine. Dystonic disorder [8A02] [128]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Imipramine and Ingrezza. Dystonic disorder [8A02] [129]
Fenfluramine DM0762O Moderate Additive serotonergic effects by the combination of Imipramine and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [130]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Imipramine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [131]
Stiripentol DMMSDOY Moderate Decreased metabolism of Imipramine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [132]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Imipramine caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [133]
Carbamazepine DMZOLBI Moderate Increased metabolism of Imipramine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [134]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Imipramine and Solifenacin. Functional bladder disorder [GC50] [100]
Mirabegron DMS1GYT Moderate Decreased metabolism of Imipramine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [135]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Imipramine and Tolterodine. Functional bladder disorder [GC50] [100]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Imipramine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [136]
Itraconazole DMCR1MV Moderate Decreased metabolism of Imipramine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [137]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Imipramine and Pentamidine. Fungal infection [1F29-1F2F] [105]
Terbinafine DMI6HUW Moderate Decreased metabolism of Imipramine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [138]
Miconazole DMPMYE8 Moderate Decreased metabolism of Imipramine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [137]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Imipramine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [137]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Imipramine and Propantheline. Gastric ulcer [DA60] [100]
Cimetidine DMH61ZB Moderate Decreased metabolism of Imipramine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [139]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Imipramine and Cisapride. Gastro-oesophageal reflux disease [DA22] [105]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Imipramine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [105]
Acetazolamide DM1AF5U Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Imipramine caused by Acetazolamide mediated altered urine pH. Glaucoma [9C61] [140]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Imipramine when combined with Isoflurophate. Glaucoma [9C61] [119]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Imipramine and Brimonidine. Glaucoma [9C61] [141]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Imipramine when combined with Pilocarpine. Glaucoma [9C61] [119]
Carvedilol DMHTEAO Moderate Increased plasma concentrations of Imipramine and Carvedilol due to competitive inhibition of the same metabolic pathway. Heart failure [BD10-BD1Z] [133]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Imipramine and Procarbazine. Hodgkin lymphoma [2B30] [102]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Imipramine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [142]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Imipramine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [143]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Imipramine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [144]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Imipramine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [145]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Imipramine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [146]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Imipramine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [105]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Imipramine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [142]
Atazanavir DMSYRBX Moderate Decreased metabolism of Imipramine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [142]
Teriflunomide DMQ2FKJ Moderate Increased metabolism of Imipramine caused by Teriflunomide mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [111]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Imipramine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [111]
Verapamil DMA7PEW Moderate Decreased metabolism of Imipramine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [147]
Labetalol DMK8U72 Moderate Increased plasma concentrations of Imipramine and Labetalol due to competitive inhibition of the same metabolic pathway. Hypertension [BA00-BA04] [133]
Givosiran DM5PFIJ Moderate Decreased metabolism of Imipramine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [148]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Imipramine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [149]
Propiomazine DMKY8V1 Moderate Increased plasma concentrations of Imipramine and Propiomazine due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [150]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Imipramine and ITI-007. Insomnia [7A00-7A0Z] [100]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Imipramine and Polyethylene glycol. Irritable bowel syndrome [DD91] [105]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Imipramine and Clidinium. Irritable bowel syndrome [DD91] [100]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Imipramine and Dicyclomine. Irritable bowel syndrome [DD91] [100]
Physostigmine DM2N0TO Moderate Antagonize the effect of Imipramine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [110]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Imipramine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [106]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Imipramine and Crizotinib. Lung cancer [2C25] [151]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Imipramine and Porfimer Sodium. Lung cancer [2C25] [152]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Imipramine and Ceritinib. Lung cancer [2C25] [105]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Imipramine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [153]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Imipramine and Osimertinib. Lung cancer [2C25] [154]
Capmatinib DMYCXKL Moderate Decreased metabolism of Imipramine caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [155]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Imipramine and Selpercatinib. Lung cancer [2C25] [106]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Imipramine and Lumefantrine. Malaria [1F40-1F45] [111]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Imipramine and Halofantrine. Malaria [1F40-1F45] [156]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Imipramine and Chloroquine. Malaria [1F40-1F45] [157]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Imipramine and Quinine. Malaria [1F40-1F45] [105]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Imipramine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [106]
IPI-145 DMWA24P Moderate Decreased metabolism of Imipramine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [158]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Imipramine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [159]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Imipramine and Vemurafenib. Melanoma [2C30] [105]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Imipramine and LGX818. Melanoma [2C30] [160]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Imipramine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [106]
Ethinyl estradiol DMODJ40 Minor Decreased metabolism of Imipramine caused by Ethinyl estradiol. Menopausal disorder [GA30] [123]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Imipramine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [161]
Exjade DMHPRWG Moderate Decreased metabolism of Imipramine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [162]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Imipramine and Flibanserin. Mood disorder [6A60-6E23] [163]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Imipramine and Panobinostat. Multiple myeloma [2A83] [164]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Imipramine and Thalidomide. Multiple myeloma [2A83] [165]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Imipramine and Siponimod. Multiple sclerosis [8A40] [111]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Imipramine and Fingolimod. Multiple sclerosis [8A40] [105]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Imipramine and Ozanimod. Multiple sclerosis [8A40] [166]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Imipramine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [106]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Imipramine and Nilotinib. Myeloproliferative neoplasm [2A20] [105]
Imatinib DM7RJXL Moderate Decreased metabolism of Imipramine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [167]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Imipramine and Dasatinib. Myeloproliferative neoplasm [2A20] [168]
Modafinil DMYILBE Moderate Decreased metabolism of Imipramine caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [111]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Imipramine and Phenindamine. Nasopharyngitis [CA00] [100]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Imipramine and Dimenhydrinate. Nausea/vomiting [MD90] [100]
Promethazine DM6I5GR Moderate Increased plasma concentrations of Imipramine and Promethazine due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [150]
Rolapitant DM8XP26 Moderate Decreased metabolism of Imipramine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [169]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Imipramine and Cyclizine. Nausea/vomiting [MD90] [100]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Imipramine and Granisetron. Nausea/vomiting [MD90] [105]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Imipramine and Dolasetron. Nausea/vomiting [MD90] [105]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Imipramine and Ondansetron. Nausea/vomiting [MD90] [105]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Imipramine and Entrectinib. Non-small cell lung cancer [2C25] [111]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Imipramine and Sibutramine. Obesity [5B80-5B81] [170]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Imipramine and Lorcaserin. Obesity [5B80-5B81] [171]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Imipramine and Dexfenfluramine. Obesity [5B80-5B81] [98]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Imipramine and Levomethadyl Acetate. Opioid use disorder [6C43] [106]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Imipramine and Lofexidine. Opioid use disorder [6C43] [106]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Imipramine and Apraclonidine. Optic nerve disorder [9C40] [172]
Valdecoxib DMAY7H4 Minor Decreased metabolism of Imipramine caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [106]
Olaparib DM8QB1D Moderate Increased metabolism of Imipramine caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [111]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Imipramine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [173]
Altretamine DMKLAYG Moderate Additive hypotensive effects by the combination of Imipramine and Altretamine. Ovarian cancer [2C73] [174]
Pentazocine DM1XBHS Moderate Additive CNS depression effects by the combination of Imipramine and Pentazocine. Pain [MG30-MG3Z] [108]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Imipramine and Dextropropoxyphene. Pain [MG30-MG3Z] [175]
Butorphanol DM5KYPJ Moderate Additive CNS depression effects by the combination of Imipramine and Butorphanol. Pain [MG30-MG3Z] [108]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Imipramine and Oxymorphone. Pain [MG30-MG3Z] [108]
Aspirin DM672AH Moderate Increased plasma concentration of Imipramine and Aspirin due to competitive binding of plasma proteins. Pain [MG30-MG3Z] [176]
Diflunisal DM7EN8I Moderate Increased plasma concentration of Imipramine and Diflunisal due to competitive binding of plasma proteins. Pain [MG30-MG3Z] [176]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Imipramine and Levorphanol. Pain [MG30-MG3Z] [108]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Imipramine and Dezocine. Pain [MG30-MG3Z] [108]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Imipramine and Flavoxate. Pain [MG30-MG3Z] [100]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Imipramine and Nalbuphine. Pain [MG30-MG3Z] [108]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Imipramine and Buprenorphine. Pain [MG30-MG3Z] [108]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Imipramine and Hydrocodone. Pain [MG30-MG3Z] [108]
Oxycodone DMXLKHV Moderate Additive CNS depression effects by the combination of Imipramine and Oxycodone. Pain [MG30-MG3Z] [108]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Imipramine and Triclabendazole. Parasitic worm infestation [1F90] [105]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Imipramine and Safinamide. Parkinsonism [8A00] [166]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Imipramine and Rasagiline. Parkinsonism [8A00] [102]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Imipramine and Biperiden. Parkinsonism [8A00] [100]
Levodopa DMN3E57 Minor Altered absorption of Imipramine due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [177]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Imipramine and Pimavanserin. Parkinsonism [8A00] [178]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Imipramine and Orphenadrine. Parkinsonism [8A00] [100]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Imipramine and Apomorphine. Parkinsonism [8A00] [105]
Abametapir DM2RX0I Moderate Decreased metabolism of Imipramine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [179]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Imipramine and Methylscopolamine. Peptic ulcer [DA61] [100]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Imipramine and Famotidine. Peptic ulcer [DA61] [111]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Imipramine and Macimorelin. Pituitary gland disorder [5A60-5A61] [180]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Imipramine and Lefamulin. Pneumonia [CA40] [181]
Choline salicylate DM8P137 Moderate Increased plasma concentration of Imipramine and Choline salicylate due to competitive binding of plasma proteins. Postoperative inflammation [1A00-CA43] [176]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Imipramine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [182]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Imipramine and Degarelix. Prostate cancer [2C82] [106]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Imipramine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [183]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Imipramine and Nilutamide. Prostate cancer [2C82] [106]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Imipramine and Enzalutamide. Prostate cancer [2C82] [106]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Imipramine and Flutamide. Prostate cancer [2C82] [106]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Imipramine and Relugolix. Prostate cancer [2C82] [106]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Imipramine and Bicalutamide. Prostate cancer [2C82] [106]
Levomepromazine DMIKFEL Moderate Increased plasma concentrations of Imipramine and Levomepromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [150]
Fluphenazine DMIT8LX Moderate Increased plasma concentrations of Imipramine and Fluphenazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [150]
Triflupromazine DMKFQJP Moderate Increased plasma concentrations of Imipramine and Triflupromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [150]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Imipramine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [184]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Imipramine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [185]
Salsalate DM13P4C Moderate Increased plasma concentration of Imipramine and Salsalate due to competitive binding of plasma proteins. Rheumatoid arthritis [FA20] [176]
Celecoxib DM6LOQU Moderate Decreased metabolism of Imipramine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [186]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Imipramine and Quetiapine. Schizophrenia [6A20] [105]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Imipramine and Mesoridazine. Schizophrenia [6A20] [105]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Imipramine and Thioridazine. Schizophrenia [6A20] [187]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Imipramine and Aripiprazole. Schizophrenia [6A20] [100]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Imipramine and Iloperidone. Schizophrenia [6A20] [105]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Imipramine and Paliperidone. Schizophrenia [6A20] [105]
Haloperidol DM96SE0 Major Decreased metabolism of Imipramine caused by Haloperidol mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [188]
Perphenazine DMA4MRX Moderate Increased plasma concentrations of Imipramine and Perphenazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [150]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Imipramine and Molindone. Schizophrenia [6A20] [100]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Imipramine and Thiothixene. Schizophrenia [6A20] [100]
Trifluoperazine DMKBYWI Moderate Increased plasma concentrations of Imipramine and Trifluoperazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [150]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Imipramine and Risperidone. Schizophrenia [6A20] [100]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Imipramine and Amisulpride. Schizophrenia [6A20] [189]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Imipramine and Asenapine. Schizophrenia [6A20] [105]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Imipramine and Pimozide. Schizophrenia [6A20] [106]
Salicyclic acid DM2F8XZ Moderate Increased plasma concentration of Imipramine and Salicyclic acid due to competitive binding of plasma proteins. Seborrhoeic dermatitis [EA81] [176]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Imipramine and Fentanyl. Sensation disturbance [MB40] [98]
Sufentanil DMU7YEL Moderate Additive CNS depression effects by the combination of Imipramine and Sufentanil. Sensation disturbance [MB40] [108]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Imipramine and Vardenafil. Sexual dysfunction [HA00-HA01] [105]
Larotrectinib DM26CQR Moderate Decreased metabolism of Imipramine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [111]
Armodafinil DMGB035 Moderate Decreased metabolism of Imipramine caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [111]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Imipramine and LEE011. Solid tumour/cancer [2A00-2F9Z] [105]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Imipramine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [105]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Imipramine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [106]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Imipramine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [105]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Imipramine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [105]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Imipramine and Adenosine. Supraventricular tachyarrhythmia [BC81] [105]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Imipramine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [190]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Imipramine and Lenvatinib. Thyroid cancer [2D10] [105]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Imipramine and Cabozantinib. Thyroid cancer [2D10] [106]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Imipramine and Papaverine. Tonus and reflex abnormality [MB47] [191]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Imipramine and Tizanidine. Tonus and reflex abnormality [MB47] [192]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Imipramine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [184]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Imipramine and Tacrolimus. Transplant rejection [NE84] [105]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Imipramine and Atropine. Unspecific substance harmful effect [NE6Z] [100]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Imipramine and Astemizole. Vasomotor/allergic rhinitis [CA08] [105]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Imipramine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [100]
Methdilazine DMAUHQX Moderate Increased plasma concentrations of Imipramine and Methdilazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [150]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Imipramine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [100]
Trimeprazine DMEMV9D Moderate Increased plasma concentrations of Imipramine and Trimeprazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [193]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Imipramine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [100]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Imipramine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [100]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Imipramine and Azatadine. Vasomotor/allergic rhinitis [CA08] [100]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Imipramine and Procainamide. Ventricular tachyarrhythmia [BC71] [105]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Imipramine and Propafenone. Ventricular tachyarrhythmia [BC71] [194]
Flecainide DMSQDLE Moderate Decreased metabolism of Imipramine caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [194]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Imipramine and Amiodarone. Ventricular tachyarrhythmia [BC71] [105]
⏷ Show the Full List of 255 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 30 E00456 3000709 Colorant
Docusate sodium E00563 23673837 Surfactant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Calcium phosphate E00298 24456 Anticaking agent; Buffering agent; Desiccant; Diluent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Ferrous oxide E00241 14945 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 35 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Imipramine 100 mg capsule 100 mg Oral Capsule Oral
Imipramine 125 mg capsule 125 mg Oral Capsule Oral
Imipramine 150 mg capsule 150 mg Oral Capsule Oral
Imipramine 75 mg capsule 75 mg Oral Capsule Oral
Imipramine 25 mg tablet 25 mg Oral Tablet Oral
Imipramine 50 mg tablet 50 mg Oral Tablet Oral
Imipramine 10 mg tablet 10 mg Oral Tablet Oral
Imipramine Hydrochloride 10mg tablet 10mg Tablet Oral
Imipramine Hydrochloride 25mg tablet 25mg Tablet Oral
Imipramine Hydrochloride 50mg tablet 50mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 357).
2 Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use
5 BDDCS applied to over 900 drugs
6 Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet. 1990 May;18(5):346-64.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
10 Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83.
11 Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
12 Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
13 QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother. 2005 Mar;39(3):543-6.
14 Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
15 Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7.
16 Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
17 Catalysis of drug oxidation during embryogenesis in human hepatic tissues using imipramine as a model substrate. Drug Metab Dispos. 1999 Nov;27(11):1306-8.
18 Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
19 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
20 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
21 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
22 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
23 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
25 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
28 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
29 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
30 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
31 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
32 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
33 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
34 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
35 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
36 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
37 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
38 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
39 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
40 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
41 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
42 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
43 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
44 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
45 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
46 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
47 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
48 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
49 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
50 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
51 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
52 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
53 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
54 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
55 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
56 Drug Interactions Flockhart Table
57 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
58 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
59 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
60 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
61 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
62 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
63 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
64 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
65 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
66 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
67 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
68 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
69 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
70 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
71 Drugs that may have potential CYP2B6 interactions.
72 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
73 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
74 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
75 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
76 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
77 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
78 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
79 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
80 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
81 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
82 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
83 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
84 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
85 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
86 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
87 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
88 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
89 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
90 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
91 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
92 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
93 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
94 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
95 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
96 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
97 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
98 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
99 Aranow AB, Hudson JI, Pope HG, et al "Elevated antidepressant plasma levels after addition of fluoxetine." Am J Psychiatry 146 (1989): 911-3. [PMID: 2787124]
100 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
101 Albers LJ, Reist C, Helmeste D, Vu R, Tang SW "Paroxetine shifts imipramine metabolism." Psychiatry Res 59 (1996): 189-96. [PMID: 8930024]
102 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
103 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
104 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
105 Canadian Pharmacists Association.
106 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
107 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
108 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
109 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
110 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
111 Cerner Multum, Inc. "Australian Product Information.".
112 Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
113 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
114 Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
115 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
116 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
117 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
118 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
119 Multum Information Services, Inc. Expert Review Panel.
120 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
121 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
122 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
123 Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
124 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
125 Cerner Multum, Inc. "Canadian Product Information.".
126 Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7. [PMID: 7068940]
127 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
128 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
129 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
130 Fogelson DL "Fenfluramine and the cytochrome P450 system." Am J Psychiatry 154 (1997): 436-7. [PMID: 9054800]
131 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
132 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
133 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
134 Brosen K, Kragh-Sorensen P "Concomitant intake of nortriptyline and carbamazepine." Ther Drug Monit 15 (1993): 258-60. [PMID: 8333008]
135 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
136 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
137 Dorsey ST, Biblio LA "Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline." Am J Emerg Med 18 (2000): 227-9. [PMID: 10750939]
138 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
139 Abernethy DR, Greenblatt DJ, Shader RI "Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability." J Pharmacol Exp Ther 229 (1984): 702-5. [PMID: 6726654]
140 Gram LF, Kofod B, Christiansen J, Rafaelsen OJ "Imipramine metabolism: pH-dependent distribution and urinary excretion." Clin Pharmacol Ther 12 (1971): 239-44. [PMID: 5554940]
141 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
142 Eap CB, Bender S, Gastpar M, et al "Steady state plasma levels of the enantiomers of trimipramine and its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients." Ther Drug Monit 22 (2000): 209-14. [PMID: 10774635]
143 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
144 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
145 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
146 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
147 Hermann DJ, Krol TF, Dukes GE, et al "Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine." J Clin Pharmacol 32 (1992): 176-83. [PMID: 1613128]
148 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
149 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
150 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
151 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
152 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
153 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
154 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
155 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
156 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
157 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
158 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
159 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
160 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
161 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
162 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
163 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
164 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
165 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
166 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
167 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
168 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
169 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
170 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
171 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
172 Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
173 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
174 Bruckner HW, Schleifer SJ "Orthostatic hypotension as a complication of hexamethylmelamine antidepressant interaction." Cancer Treat Rep 67 (1983): 516. [PMID: 6406063]
175 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
176 Juarez-Olguin H, Jung-Cook H, Flores-Perez J, Asseff IL "Clinical Evidence of an Interaction Between Imipramine and Acetylsalicylic Acid on Protein Binding in Depressed Patients." Clin Neuropharmacol 25 (2002): 32-36. [PMID: 11852294]
177 Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N "Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man." Neurology 25 (1975): 1029-34. [PMID: 1237820]
178 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
179 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
180 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
181 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
182 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
183 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
184 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
185 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
186 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
187 Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
188 Alter P, Tontsch D, Grimm W "Doxepin-induced torsade de pointes tachycardia." Ann Intern Med 135 (2001): 384-5. [PMID: 11529713]
189 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
190 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
191 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
192 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
193 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
194 Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]